Tier 3 — preclinical
Coenzyme Q10 phospholipidic vesicular formulations for treatment of androgenic alopecia: ex vivo permeation and clinical appraisal
Expert Opinion on Drug Delivery
2021
18(10):1513-1522
Bibliography
- PubMed
- PMID 34047661
Study snapshot
| Design | Topical formulation development with ex vivo permeation and human clinical appraisal |
|---|---|
| Model | Patients with androgenic alopecia plus ex vivo skin testing |
| Sample | |
| Intervention | Topical CoQ10 transethosomal formulation versus CoQ10 solution |
| Duration | |
| Endpoints | Skin deposition and permeation; Clinical alopecia response; Dermoscopic response |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



